Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Sep. 30, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 139,439	$ 184,434
Accounts receivable	239	10,255
Prepaid expenses	6,761	4,362
Other current assets	8,892	2,191
Marketable securities	0	126,728
Short term investments	277,057	56,627
TOTAL CURRENT ASSETS	432,388	384,597
Property and equipment, net	71,904	48,675
Intangible assets, net	12,387	13,663
Long term investments	165,920	245,595
Right-of-use assets	68,908	17,346
Other assets	275	272
TOTAL ASSETS	751,782	710,148
CURRENT LIABILITIES
Accounts payable	5,894	9,457
Accrued expenses	32,499	14,001
Accrued payroll and benefits	2,648	9,773
Lease liabilities	2,883	2,250
Deferred revenue	84,288	111,055
TOTAL CURRENT LIABILITIES	128,212	146,536
LONG-TERM LIABILITIES
Lease liabilities, net of current portion	78,231	23,295
Deferred revenue, net of current portion	71,162	131,495
TOTAL LONG-TERM LIABILITIES	149,393	154,790
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders’ equity:
Common stock, $0.001 par value; 145,000 shares authorized; 105,795 and 104,327 shares issued and outstanding as of June 30, 2022 and September 30, 2021, respectively	198	197
Additional paid-in capital	1,189,113	1,053,386
Accumulated other comprehensive loss	(140)	(69)
Accumulated deficit	(735,244)	(644,692)
TOTAL ARROWHEAD PHARMACEUTICALS INC. STOCKHOLDERS' EQUITY	453,927	408,822
Noncontrolling Interest	20,250	0
TOTAL STOCKHOLDERS’ EQUITY	474,177	408,822
TOTAL LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY	$ 751,782	$ 710,148